Showing 7641-7650 of 9083 results for "".
- DermTech Seeks to #Stickit2Melanomahttps://practicaldermatology.com/news/dermtech-seeks-to-stickit2melanoma/2461184/DermTech is bringing back its #Stickit2Melanoma campaign in honor of Melanoma and Skin Cancer Awareness Month. First launched in 2021, the campaign supports DermTech’s core mission to help end deaths from melanoma through early and reliable detection. For every
- Pathologist Survey: Melanoma Is Overdiagnosedhttps://practicaldermatology.com/news/pathologist-survey-melanoma-is-overdiagnosed/2461180/Many pathologists agree that overdiagnosis of skin cancer happens, but don’t change diagnosis behavior, according to a new study. “Overdiagnosis is the diagnosis of disease that will not harm a person in their lifetime. If melanoma is being overdiagnosed, it means that too m
- ePatch Using Electrical Field Stimulation Shows Promise for Wound Healinghttps://practicaldermatology.com/news/epatch-using-electrical-field-stimulation-shows-promise-for-wound-healing/2461175/A “smart” flexible electric patch (ePatch) developed by a collaborative team from the Terasaki Institute for Biomedical Innovation promises to address the challenges posed by existing electrical field (EF) stimulation devices for wound healing and offers many uniquely advantageous fea
- Lumenis Has Launched triLift for Facial Stimulationhttps://practicaldermatology.com/news/lumenis-has-launched-trilift-for-facial-stimulation/2461173/Lumenis Be, Ltd., has launched triLift, a facial stimulation device targeting three aging elements—structure, contour, and texture—by treating the three tissue layers. The device affects the muscl
- Study: Improved Survival Seen for DecisionDx-Melanoma Tested Patientshttps://practicaldermatology.com/news/study-improved-survival-seen-for-decisiondx-melanoma-tested-patients/2461168/Melanoma patients tested with DecisionDx-Melanoma plus traditional clinicopathologic factors showed improved survival compared to patients tested with only traditional clinicopathologic factors available to determine their treatment and follow-up plan, according to data presented the 18th Europea
- Virtual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® Coming Soonhttps://practicaldermatology.com/news/virtual-skin-cancer-symposium-symposium-for-inflammatory-skin-disease-coming-soon/2461166/The 2nd Annual Skin Cancer Symposium® + Symposium for Inflammatory Skin Disease® (SCS + SISD) will be held virtually June 10-12, 2022. Fifteen well-known speakers will deliver 15 hours of CME credit on topics such as BCC, SCC, melanoma, actinic keratosis, dermosc
- FDA Cracks Down on OTC HQ Productshttps://practicaldermatology.com/news/fda-cracks-down-on-otc-hq-products/2461164/The US Food and Drug Administration is cracking down on over-the-counter (OTC) skin lightening products containing hydroquinone (HQ) that do not meet the requirements to be legally sold as OTC drugs. The group issued warning letters to 12 companies explaining that all OTC skin lightenin
- Castle's Non-Invasive Gene Expression Profile Test Can Predict Response to Systemic Therapy in Patients with Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/castles-gene-expression-profile-test-can-predict-response-to-systemic-therapy-in-patients-with-inflammatory-skin-diseases/2461163/Castle Biosciences, Inc.’s non-invasive skin scraping technique produces sufficient ribonucleic acid (RNA) to assess reproducible gene expression for its inflammatory skin disease pipeline test, according to a poster was presented at the 4th Annual Revolutionizing Atopic Der
- TOOsonix System ONE-M BCC Clinical Trial Updatehttps://practicaldermatology.com/news/toosonix-system-one-m-bcc-clinical-trial-update/2461162/The first basal cell carcinoma (BCC) patients have been treated with TOOsonix A/S’s System ONE-M device. The TOOsonix high-intensity focused ultrasound (HIFU) delivers highly accurate doses of energy to focal points in a chosen depth. It operates at 20 MHz to
- New Survey Reveals Negative Impact of Psoriasis on Mental Healthhttps://practicaldermatology.com/news/new-survey-reveals-negative-impact-of-psoriasis-on-mental-health/2461159/Arcutis Biotherapeutics, Inc. recently shared findings from the Skin Insights: Uncovering Psoriasis Survey, a national survey of 507 adults 18+ diagnosed with plaque psoriasis who are on topical treatments. The online survey was conducted by The Harris Poll and was designed to reveal insight